• By ICR Secretariat
• Posted Wednesday, August 2, 2023

TauRx’s deliver Alzheimer’s disease therapy results

https://www.pharmatimes.com/news/taurxs_deliver_alzheimers_disease_therapy_results_1494575

TauRx Pharmaceuticals – a company focused on Alzheimer’s disease (AD) research – has announced results from its pivotal phase 3 LUCIDITY trial.

The study measured the effect of hydromethylthionine mesylate (HMTM) on neurofilament light change (NfL) – a vital brain neurodegeneration biomarker.